spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

GE Healthcare advances the delivery of cell therapies with new thawing technology

GE Healthcare Life Sciences

VIA Thaw CB1000 offers automated, dry thawing of cryo-bags to address key cell therapy challenges

CHALFONT ST. GILES, UK - 5 September 2017 - GE Healthcare today introduced the first in its VIA Thaw series, the VIA Thaw CB1000 for thawing large volumes of cell therapies cryopreserved in cryo-bags. This range of innovative automated, dry thawing units provides users with control over the thawing of sensitive therapies, and addresses key challenges faced by cell therapy companies. Designed to overcome the multiple inconsistent elements in standard water bath thawing practice, the VIA Thaw series delivers a simple, reproducible and traceable recovery system that maintains cell viability to prevent loss of therapeutic effect.

With around 900 cell therapy clinical trials underway worldwide and a handful of products approved as treatments1, the emergence of cell therapies will potentially change the landscape of healthcare. However, maintaining cell potency throughout the manufacture and cryogenic cold chain (cryochain) of these treatments is a major challenge. Cell thawing is the final and least controlled part of the cryochain. The process is often carried out in water baths across multiple sites, with inconsistencies due to subjective determination of the thaw endpoint and risk of water-borne contamination. The collection and collation of data from thaw sites, often by paper records, also impedes therapy development. In 2015, the leading UK-based cell therapy organization, the Cell and Gene Therapy Catapult, identified these barriers to the commercialization of cell therapies and approached Asymptote (now part of GE Healthcare) to apply its expertise in cryochain technology to find the solution.

Commercially available from today, GE Healthcare’s VIA Thaw CB1000, standardizes and streamlines the recovery of cryopreserved samples with a system which captures a complete, auditable thaw record. Combining automation with dry conduction thawing, it enables the thaw endpoint to be precisely determined, and eliminates the contamination risk associated with water baths. Thaw profiles can be customized to every cell therapy sample and transmitted to thawers across multiple sites to ensure consistent sample thawing. All VIA Thaw CB1000 units have a ‘lock-down’ option to limit the operator to a single pre-set profile and minimize the risk of error. Electronic data logging creates a record of each step in the thawing process and enables sources of variation to be identified quickly. All VIA Thaw units integrate with the GE’s digital my.Cryochain platform, to standardize and audit thawing processes from any web-browser.

Ger Brophy, General Manager, Cell Therapy, GE Healthcare said: “As the number of cell therapies increases, GE Healthcare has been focusing on creating solutions that safeguard the manufacture and delivery of these therapies. The new VIA Thaw series will provide certainty in cell thawing, through an automated, dry process, and complete visibility over the thawing procedure. This technology has the ability to transform the final stage of cell therapy and help advance the industrialization and delivery of these potentially life-saving therapies.”

VIA Thaw CB1000 is available now for research use in laboratory and clinical trial settings. The VIA Thaw SC2 for thawing cell therapies contained in 2 mL screw cap vials will be commercially available soon. Both units will be presented at the CAR-TCR Summit 2017 (5-8 September in Boston, MA).

The VIA Thaw series of automated thawers are intended for research use only. These are not medical devices and have not undergone medical device registration, clearance, or approval with any Regulatory Authority. The User is solely responsible for obtaining the appropriate IND/BLA/NDA, or equivalent approvals, for any clinical application. For more information visit asymptote.co.uk/viathaw.

1https://alliancerm.org/page/arm-q2-2017-quarterly-data-report
phone + 1 800 526 3593
email cs-us@ge.com
web www.gelifesciences.com
email P.O. Box 643065 Pittsburgh, PA 15264-3065 United States of America
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Countdown to the UK’s leading production line event begins

The manufacturing sector has just achieved its longest period of expansion since 1968, boosted by global economic growth and the weakened pound, while early signs reveal that Britain’s manufacturers are on track to outpace the rest of the economy – setting the year on a strong path for growth.
More info >>


White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

Industry Events

SMi presents the 2nd annual conference on Pharmaceutical Microbiology West Coast

6-8 June 2018, Crowne Plaza, San Diego, CA, USA

SMi proudly presents the 2nd Annual Pharmaceutical Microbiology West Coast Conference, in San Diego, USA, on the 7th and 8th of June 2018. Delivering updates and promoting discussion on key challenges and developments within the pharmaceutical microbiology industry.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement